Odanacatib is an inhibitor of cathepsin K that displays anti-osteoporotic and anti-resorptive activities. Odanacatib protects bone against periapical infection and disease by preventing pathogenic infection, immune responses, and bone erosion. This compound is currently in clinical trials as a potential treatment for osteoporosis, where it inhibits bone resorption and increases bone mineral density.
| Cas No. | 603139-19-1 |
|---|---|
| Purity | ≥99% |
| Formula | C25H27F4N3O3S |
| Formula Wt. | 525.56 |
| IUPAC Name | N-(1-Cyanocyclopropyl)-4-fluoro-N2-{(1S)-2,2,2-trifluoro-1-[4'-(methylsulfonyl)-4-biphenylyl]ethyl}-L-leucinamide |
| Synonym | MK0822 |
| Appearance | White powder |
| Store Temp | -20°C |
|---|---|
| Ship Temp | Ambient |
| Info Sheet | O1200 Info Sheet PDF |
|---|
Bone HG, Dempster DW, Eisman JA, et al. Odanacatib for the treatment of postmenopausal osteoporosis: development history and design and participant characteristics of LOFT, the Long-Term Odanacatib Fracture Trial. Osteoporos Int. 2015 Feb;26(2):699-712. PMID: 25432773.
Hao L, Chen W, McConnell M, et al. A small molecule, Odanacatib, inhibits inflammation and bone loss caused by endodontic disease. Infect Immun. 2015 Jan 12. [Epub ahead of print]. PMID: 25583522.
Gauthier JY, Chauret N, Cromlish W, et al. The discovery of odanacatib (MK-0822), a selective inhibitor of cathepsin K. Bioorg Med Chem Lett. 2008 Feb 1;18(3):923-8. PMID: 18226527.
